ALIM - Alimera Sciences, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
7.35
-0.05 (-0.68%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close7.40
Open7.68
Bid7.10 x 1000
Ask8.50 x 2200
Day's Range7.23 - 7.65
52 Week Range0.00 - 9.98
Volume20,849
Avg. Volume202,309
Market Cap36.483M
Beta (5Y Monthly)2.11
PE Ratio (TTM)N/A
EPS (TTM)-2.55
Earnings DateFeb 16, 2020 - Feb 20, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.63
  • 2 Healthcare Stocks Set to Rally into the New Year
    TipRanks

    2 Healthcare Stocks Set to Rally into the New Year

    The psychology of investing presents an interesting conundrum. When a stock soars, the natural tendency is to want to get in on the action, as the FOMO kicks in and the allure of further gains is hard to resist. This is often the wrong choice as the stock will likely be sold off at a premium to latecomers.Conversely, a beaten-down stock induces tremors of fear. The inevitable concern about the stock’s low valuation and negative market sentiment can cause potential investors to avoid backing what appears to be a losing horse. This is sometimes the case, but other times share price weakness represents the best time to get in before a stock sets off on its upward trajectory.So how can you tell the losers from the winners? While nothing is certain, the experts on Wall Street can lend a helping hand. In a recent note to clients, B. Riley FBR analyst Andrew D’Silva highlights stocks in the healthcare sector which he thinks are set to make headway in 2020.“Each company either exited 2019 on a strong footing, where momentum is poised to carry over into 2020, or has fallen out of favor, but execution will result in a reversal,” the analyst commented.Using TipRanks’ Stock Comparison tool, we were able to zoom in on 2 of D’Silva’s choices. Whether beaten-down or flying high, all have plenty of room for upside, and all currently have a Strong Buy consensus rating from the Street. Let's take a closer look:Alimera Sciences (ALIM)Alimera Sciences had a miserable 2019. The retinal disease focused company lost 30% of its share price over the year. So far, 2020 has not been kinder, either. The share price is down by almost 10% year-to-date.So, should investors stay away? Absolutely not, says D’Silva. Now is the time to reassess the biopharma’s potential.The drop, he says, was instigated by the significant impact of 2Q19 results missing expectations, which were mostly attributed to a significant loss of domestic sales force. During 1H19, “several companies launched ophthalmic offerings and established/expanded their sales teams.” The numerous employment opportunities contributed to a depletion of Alimera’s own sales team.“We believe this compounded investor working capital concerns, as ALIM's $40 million term loan's interest-only period was scheduled to end within a year's time,” D’Silva noted.However, the analyst expects a “significant reversal this year.” He cited a resolution to the company’s sales force turnover issues, an expanding international footprint, and the “significant milestone” of management’s positive 2020 adjusted EBITDA guidance as reasons for the anticipated turnaround. Furthermore, a new debt refinancing arrangement “cleared a significant working capital overhang.”D’Silva noted, “While we expected that the company would refinance its term loan, we believe this should remove a significant trading overhang related to investor fears that ALIM would need to raise capital through a highly dilutive equity financing to fund operations and meet its debt obligation.”D'Silva, therefore, reiterated a Buy rating on Alimera along with a price target of $24. With ALIM currently trading at $6.91, the upside potential comes in at a massive 243%. (To watch D’Silva’s track record, click here)All in all, three analysts are currently keeping track of the eye disease specialist and all three see better days ahead too, rating the stock a Buy. With an average price target of $20.50, the figure suggests potential upside of nearly 200%. (See Alimera price targets and analyst ratings on TipRanks)CytoSorbents Corporation (CTSO)In a similar vein to Alimera, CytoSorbents is a beaten-down stock, displaying even further wreckage. It lost 52% of its share price during last year’s bull run.CTSO’s blood purification technologies are used to control deadly inflammation in critically-ill and cardiac surgery patients. After exhibiting revenue growth of 51% in 2018, the growth curve slowed down to 9% year-over-year in the first three quarters of 2019.D’Silva explained, “While the slower top-line growth could be concerning at first glance, the two primary reasons for the slowdown were related to two CS distributors and Fresenius Medical Care—which, together, accounted for ~15%-20% of the CTSO top line in 2018—entering 2019 with excess inventory, as well as CTSO running into sales-force bandwidth issues in its largest market, Germany.”With CTSO commencing sales in Poland, Sweden, Denmark, Norway, and the Netherlands, D’Silva foresees a turnaround in the months ahead.“While we don't anticipate CTSO realized significant benefits from new direct sales regions in 4Q19, as most new sales hires were onboarded in 2H19, we do expect CTSO's expanded footprint to provide a significant benefit this year… Meanwhile, We believe there are numerous clinical and regulatory catalysts are on the horizon that should be significant value drivers for the stock if successful,” said the analyst.As a result, D’Silva kept his Buy rating and supports it with an ambitious $12 price target. Attaining this number will provide a very healthy 210% gain in the next twelve months.Does the Street agree? Those who are taking notice certainly do. 3 Buy ratings and no Holds or Sells add up to a unanimous Strong Buy consensus rating. The recommendation comes alongside an average price target of $11 and implies upside potential of 176%. (See CytoSorbents stock-price forecast and analyst ratings)

  • GlobeNewswire

    Alimera Sciences Refinances Its Debt Facility With Solar Capital

    The amount of the new funding includes an initial tranche of $42.5 million used to repay the current facility, including principal, prepayment fees and accrued interest, and another $2.5 million tranche that will be available if Alimera achieves $30.0 million in revenue for any trailing six-month period ending on or before November 30, 2020. The interest-only period may be extended an additional six months if Alimera achieves $34.5 million in revenue for any trailing six-month period ending on or before June 30, 2022. “We are pleased that Solar Capital has agreed to extend our relationship and continue working with Alimera in support of our future growth,” said Rick Eiswirth, Alimera’s president and chief executive officer.

  • Did Hedge Funds Drop The Ball On Alimera Sciences Inc (ALIM) ?
    Insider Monkey

    Did Hedge Funds Drop The Ball On Alimera Sciences Inc (ALIM) ?

    "The global economic environment is very favorable for investors. Economies are generally strong, but not too strong. Employment levels are among the strongest for many decades. Interest rates are paused at very low levels, and the risk of significant increases in the medium term seems low. Financing for transactions is freely available to good borrowers, […]

  • PR Newswire

    Almira Sciences, Inc 13D filing

    Ronald L Chez, a private investor, files a 13D for Alimera Sciences, Inc. (NASDAQ: ALIM). Alimera returns to growth in the 3rd quarter and expects continued progress in the 4th quarter. The Company is in a strong position to succeed with their unique approach to DME.

  • GlobeNewswire

    Alimera Sciences to Participate in the LD Micro 12th Annual Main Event on December 10, 2019

    Mr. Eiswirth will provide an overview of the company’s business model and growth strategy and will be available for one-on-one meetings. For those interested in attending or for registered attendees who wish to request meetings, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

  • GlobeNewswire

    Alimera Announces Regulatory Approval for ILUVIEN® in Benelux Countries for The Treatment of Non-Infectious Posterior Uveitis

    The complete Benelux approval was achieved when The Netherlands’ Medicines Evaluation Board informed Alimera of their approval on November 6, 2019. The approval by Belgium’s Federal Agency for Medicines and Health Products was received in May of 2019, and Luxembourg’s Heads of Medicines Agencies provided its confirmation of regulatory approval in late October.

  • GlobeNewswire

    Alimera Sciences to Participate in the 31st Annual Piper Jaffray Healthcare Conference

    ATLANTA, Nov. 26, 2019 -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or “Company”), a leader in the commercialization and development of prescription ophthalmology.

  • Thomson Reuters StreetEvents

    Edited Transcript of ALIM earnings conference call or presentation 30-Oct-19 1:00pm GMT

    Q3 2019 Alimera Sciences Inc Earnings Call

  • GlobeNewswire

    Alimera Sciences Announces Effectiveness of Previously Announced Reverse Stock Split

    The certificate of amendment provides that the reverse stock split will become effective at 5:01 PM Eastern Time today, after the close of trading on The Nasdaq Global Market. Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the management of retinal diseases.

  • GlobeNewswire

    Alimera Sciences Terminates Equity Purchase Agreement

    Alimera Sciences, Inc. (ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it has terminated its $20.0 million common stock purchase agreement with Lincoln Park Capital Fund, LLC (“LPC”), effective November 12, 2019. “After assessing our expectations for the remainder of this year and plans for 2020, we have made the decision to terminate our equity purchase agreement. Having completed the third quarter of 2019 at an annualized revenue run rate in excess of $50 million, we believe we have sufficient cash on hand to fund our operations throughout 2020,” said Rick Eiswirth, president and CEO of Alimera.

  • Benzinga

    The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 7.) Collegium Pharmaceutical Inc (NASDAQ: COLL ...

  • GlobeNewswire

    Alimera Sciences Announces Board’s Approval of Reverse Stock Split Ratio

    Alimera Sciences, Inc. (ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it will effect a one-for-15 reverse stock split (reverse split) of its common stock that will become effective on November 14, 2019 after the close of trading on The Nasdaq Global Market. The reverse split is primarily intended to bring Alimera into compliance with the minimum bid price requirement for maintaining its listing on The Nasdaq Global Market.

  • GlobeNewswire

    Alimera Sciences to Participate in the 10th Annual Craig-Hallum Alpha Select Conference in New York

    Alimera Sciences, Inc. (ALIM) (“Alimera” or “Company”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that Rick Eiswirth, President and Chief Executive Officer of Alimera, and Phil Jones, the Company’s Chief Financial Officer, will participate in the 10th Annual Craig-Hallum Alpha Select Conference in New York City on November 12, 2019. The Conference will be held at the Sheraton New York Times Square Hotel 8:00AM-4:40PM Eastern Time.

  • One Thing To Remember About The Alimera Sciences, Inc. (NASDAQ:ALIM) Share Price
    Simply Wall St.

    One Thing To Remember About The Alimera Sciences, Inc. (NASDAQ:ALIM) Share Price

    Anyone researching Alimera Sciences, Inc. (NASDAQ:ALIM) might want to consider the historical volatility of the share...

  • GlobeNewswire

    Alimera Sciences Announces Third Quarter 2019 Financial Results and Provides Corporate Update

    Third Quarter and Recent Company Highlights: Consolidated Net Revenue Up 16% Compared to Third Quarter 2018International Net Revenue Up 62% Compared to Third Quarter 2018Launch.

  • Benzinga

    The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 28.) AstraZeneca plc (NYSE: AZN ) ( reported positive ...

  • GlobeNewswire

    Alimera Sciences Announces Equity Purchase Agreement for up to $20 Million with Lincoln Park Capital

    Upon entering into the agreement, LPC purchased $1.0 million of Alimera’s registered common stock at $0.50 per share, which represents a 35% premium to the closing market price of the stock on October 24, 2019. Thereafter and upon satisfaction of the conditions in the agreement, Alimera, from time to time over a 36-month period, will have the right, in its sole discretion, to sell up to an additional $19.0 million of its common stock to LPC.

  • GlobeNewswire

    Alimera Sciences to Report Third Quarter 2019 Financial Results on Tuesday, October 29, 2019 and Provide Corporate Update

    Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it will report third quarter 2019 financial results on Tuesday, October 29, 2019 after the market close. For more information, please visit www.alimerasciences.com.

  • GlobeNewswire

    Alimera Obtains Marketing Authorization for ILUVIEN® in Portugal for the Treatment of Non-Infectious Posterior Uveitis

    Alimera Sciences, Inc. (ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that INFARMED, the governmental agency that oversees the availability of medical products in Portugal, granted marketing authorization on October 1, 2019 for ILUVIEN® for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment (NIPU). Alimera will market the product directly to physicians in Portugal through its European sales organization. Alimera currently sells ILUVIEN in Portugal for the treatment of diabetic macular edema (DME).

  • GlobeNewswire

    Alimera Sciences Announces Top Line Revenue Expectation For the Third Quarter of 2019

    Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces top-line revenue guidance for the quarter ended September 30, 2019. Alimera expects to report consolidated net revenue for the third quarter of 2019 exceeding $12.8 million. This compares to $10.9 million for the second quarter of 2019 and $11.1 million in the third quarter of 2018.

  • GlobeNewswire

    Alimera Sciences Announces Clinical Data Featuring the Benefits of ILUVIEN® to be Presented at the American Academy of Ophthalmology Annual Meeting

    Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that clinical data for ILUVIEN® (fluocinolone acetonide intravitreal implant 0.19mg) will be featured in multiple papers and discussions at the Annual Meeting of the American Academy of Ophthalmology, taking place at the Moscone Center in San Francisco from October 12-15, 2019. “We are pleased to once again showcase the differentiated benefits of ILUVIEN for the treatment of DME in several new clinical papers and discussions at this year’s AAO conference,” said Rick Eiswirth, CEO of Alimera.

  • GlobeNewswire

    Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN® in Benelux Countries

    Alimera Sciences, Inc. (ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it has expanded its relationship with Horus Pharma, one of the Company’s current distributors of ILUVIEN® in Europe.

  • GlobeNewswire

    Alimera Sciences Board of Directors Approves Reverse Stock Split and 10b5-1 Stock Purchase Plan for U.S. Executive Management

    Alimera Sciences, Inc. (ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announced that its board of directors has approved a proposal to effect a reverse stock split of its common stock. The reverse stock split is expected to result in a higher per share price and a corresponding lower number of total shares issued and outstanding, which should enable Alimera to attain the minimum $1.00 per share bid price requirement for its common stock as required for continued listing on the Nasdaq Global Market. Alimera believes that a reverse stock split can help increase the marketability of its stock to a broader range of potential investors.

  • GlobeNewswire

    Alimera Sciences Launches ILUVIEN® in Germany For Non-Infectious Uveitis Indication

    Alimera Sciences, Inc. (ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it will immediately commence the launch of ILUVIEN in Germany for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIPU). Following the European Union’s Mutual Recognition Procedure in March 2019, Germany is the second country in Europe in which ILUVIEN is now commercially available to be prescribed to patients suffering from NIPU, a disease with no sustained treatment options.

  • How Much Of Alimera Sciences, Inc. (NASDAQ:ALIM) Do Institutions Own?
    Simply Wall St.

    How Much Of Alimera Sciences, Inc. (NASDAQ:ALIM) Do Institutions Own?

    Every investor in Alimera Sciences, Inc. (NASDAQ:ALIM) should be aware of the most powerful shareholder groups...